Navigation Links
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
Date:10/5/2009

PHILADELPHIA, Oct. 5 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

"Kidney cancer is a very serious disease therefore the committee's recommendation in support of pazopanib is an important step towards bringing a new, oral treatment option to advanced renal cell cancer patients," said Rafael Amado, MD, Vice President, GlaxoSmithKline Oncology R&D Unit. "We look forward to working with the FDA towards the approval of pazopanib."

RCC is the most common type of kidney cancer and accounts for approximately nine out of ten cases. It is estimated that approximately 57,700 people will be diagnosed with kidney cancer and 13,000 people will die from kidney cancer in the United States in 2009. In 2002, an estimated 208,000 new cases of kidney cancer were diagnosed globally.

The advisory committee made its decision based on Phase III pivotal trial data that were presented at the American Society of Clinical Oncology 2009 annual meeting.

About pazopanib

Pazopanib is an investigational medicine that may prevent the growth of new blood vessels to tumors, a process known as angiogenesis. All solid tumors need blood vessels to survive, and medicines in this category may halt the progression of tumor growth.

About pazopanib and clinical development

In its pivotal study, pazopanib was administered orally, once daily. Pazopanib has a broad clinical program across multiple tumor types, with study details available at www.clinicaltrials.gov. Mo
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmabs ARZERRA(TM) (ofatumumab)
4. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
5. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
6. Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
7. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
8. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
9. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... a conference call and audio webcast to discuss financial results ... closes on Thursday, July 31, 2014 at 4:30 p.m. ET. ... Date: July 31, 2014 Time: 4:30 PM ET ... International: (678) 373-0875 A webcast replay will be ...
(Date:7/28/2014)... Calif., July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... update for the second quarter ended June 30, 2014. ... 30, 2014 was $7.3 million, compared to $8.3 million for ... is a direct result of a decrease in interest expense ... the six months ended June 30, 2014 was $15.2 million, ...
(Date:7/28/2014)... Corporation (NASDAQ: LMNX ) today announced financial ... Financial and operating highlights include the following: ... 2 percent increase over the second quarter of 2013. ... a 9 percent increase over the second quarter of ... analyzers, which included 148 LX systems, 96 MAGPIX systems, ...
Breaking Medicine Technology:Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17
... PRGO ; TASE) today announced results for its ... and CEO Joseph C. Papa commented, "We are very pleased ... contributors to this strong performance were $44 million of new ... segments and another solid quarter in Nutritionals. In Consumer Healthcare, ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today ... at the Bank of America Merrill Lynch Healthcare conference in Las ... Vegas, NV Presentation date: Tuesday May 10, 2011 ... A live webcast and 30-day archive of this presentation will ...
Cached Medicine Technology:Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 2Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 3Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 4Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 5Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 6Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 7Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 8Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 9Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 10Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 11Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 12Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 13Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 14Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 15Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 16Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 17Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance 18
(Date:7/28/2014)... Cancer cells are gluttons. We have long known that ... became clear that some tumor cells are also characterized ... unlikeliness to join in an ordered set. Researchers are ... metastasis. , At EPFL, Etienne Meylan,s research team was ... for sugar and mesenchymal behavior result from the ...
(Date:7/28/2014)... Ticket Down is a reputable source ... between Manchester City and Liverpool FC at Yankee Stadium ... countless big events since it opened several years ago. It ... Yankee Stadium, however, it has been a popular destination for ... , The Yankees Stadium is the home of the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3
... increase lowers chance of hospitalization or death , ... heart failure, high doses of the drug losartan, an ... and death, a new study shows. , Though ARBs ... study focused on whether dose level makes a difference. ...
... what women should do about the new guidelines, , WEDNESDAY, ... force recommended that women wait until they,re 50 to get ... swift. , Critics such as the American Cancer Society vowed ... age 40 for women of average risk. The American ...
... ... the AnnArbor.com Business Review awarded the company top honors in the Healthcare category during ... ongoing commitment to the local community and recent completion of a $3.6 million expansion ... ...
... Apieron, Inc. has asked the court presiding over ... to raise additional grounds for invalidating Aerocrine,s broadest patent ... , In its motion, Apieron alleges that recently obtained ... Alving, Jan Lundberg, and Edward Weitzberg, inventors named on ...
... , SYDNEY, Nov. 18 Members of the Church ... Ambassadors were out in force Sunday, November 15, distributing thousands ... purpose: to inform kids of the truth about drugs so ... a new drug called Mephedrone, or "MM-Cat," that Sydney students ...
... ... a KTRK-TV, a local television news affiliate, is bringing to light a new technique ... the recovery process and the aesthetic results for patients who undergo surgical treatment for ... ...
Cached Medicine News:Health News:Heart Failure Drug May Help More in Higher Doses 2Health News:Mammography: What to Do Now? 2Health News:Mammography: What to Do Now? 3Health News:Mammography: What to Do Now? 4Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 2Health News:Terumo Heart, Inc. Wins Top Healthcare Category Honors at AnnArbor.com's 5th Annual ‘Deals Of The Year' Award Ceremony 3Health News:Scientology Volunteers Attack Drug Abuse in Sydney 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 2Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 3Health News:Texas Laparoscopic Consultants Profiled on ABC-13 TV as the Only Practice in Houston Offering Single-Incision, Quick Recovery Weight Loss Surgery 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: